Evidence map›Paper›PMID 37438612›Full record

ArticleBritish journal of cancer2023

Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study.

Siv S Brenne, Poul Henning Madsen, Inge Søkilde Pedersen, Kristian Hveem, Frank Skorpen, Henrik Bygum Krarup, Guro F Giskeødegård, Eivor A Laugsand

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Siv S BrenneDepartment of Surgery, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway. siv.s.brenne@ntnu.no.ORCID 0000-0002-6227-8388
Poul Henning MadsenMolecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
Inge Søkilde PedersenMolecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0002-9902-8040
Kristian HveemDepartment of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, N-7489, Trondheim, Norway.
Frank SkorpenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, N-7489, Trondheim, Norway.
Henrik Bygum KrarupMolecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0001-5294-2428
Guro F GiskeødegårdDepartment of Public Health and Nursing, Norwegian University of Science and Technology, NTNU, N-7489, Trondheim, Norway.ORCID 0000-0003-2157-8824
Eivor A LaugsandDepartment of Surgery, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway.
Norwegian University of Science and Technology · NOAalborg University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is often diagnosed in advanced stages. Circulating tumour DNA (ctDNA) has been proposed as an early diagnostic biomarker. However, as a screening tool, ctDNA has mainly been studied in selected populations at the time of clinical diagnosis. The aim of this study was to detect CRC by known ctDNA markers up to 2 years prior to clinical diagnosis.

methodsIn this case-control study, methylated ctDNA markers were detected in plasma samples from 106 healthy controls and 106 individuals diagnosed with CRC within 24 months following participation in The Trøndelag Health Study.

resultsThe most specific single markers were BMP3, FLI1, IKZF1, SFRP1, SFRP2, NPTX2, SLC8A1 and VIM (specificity >70%). When combining these into a panel, the CRC sensitivity was 43% (95% CI 42.7-43.4) and the CRC specificity was 86% (95% CI 85.7-86.2). The findings were reproduced in an independent validation set of samples.

conclusionsDetection of known methylated ctDNA markers of CRC is possible up to 2 years prior to the clinical diagnosis in an unselected population resembling the screening setting. This study supports the hypothesis that some patients could be diagnosed earlier, if ctDNA detection was part of the CRC screening programme.

Indexed as

Colorectal NeoplasmsDNA MethylationBiomarkers, TumorCase-Control StudiesHumansLiquid BiopsyBiomarkers, Tumor

Identifiers

PMID37438612
PMCPMC10449868
OpenAlexW4384034147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.